Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

OBJECTIVES: Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context. As an interdisc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagorski, Claire M., Hosey, Rebecca A., Moraff, Christopher, Ferguson, Aaron, Figgatt, Mary, Aronowitz, Shoshana, Stahl, Natalie E., Hill, Lucas G., McElligott, Zoe, Dasgupta, Nabarun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544173/
https://www.ncbi.nlm.nih.gov/pubmed/37777769
http://dx.doi.org/10.1186/s12954-023-00879-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544173/
https://www.ncbi.nlm.nih.gov/pubmed/37777769
http://dx.doi.org/10.1186/s12954-023-00879-7

Ejemplares similares